Iobenguane I-131

Iobenguane I-131 is a radiopharmaceutical used for both diagnostic imaging and targeted radiotherapy. It is an aralkylguanidine analog of norepinephrine that localizes to adrenergic tissue via the norepinephrine transporter. When labeled with radioactive iodine (I-131), it accumulates in neuroendocrine tumors such as pheochromocytoma and paraganglioma. The radioactive decay of iodine-131 delivers cytotoxic radiation to tumor cells expressing high levels of the norepinephrine transporter, leading to cell death and tumor necrosis. It is FDA-approved for treating unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma in patients aged 12 years or older who require systemic anticancer therapy[1][2][3][4][5]. The drug was developed by Progenics Pharmaceuticals and uses a proprietary Ultratrace process for manufacturing[8].

Brand names

AzedraAdreview

Other names

iobenguaneMIBGmeta-iodobenzylguanidine